Measles remains a major cause of morbidity and mortality worldwide among vaccine
preventable diseases. Recent decline in vaccination coverage resulted in re-emergence of …

The effectiveness of vaccination against measles, the leading cause of vaccine-preventable
deaths in infants globally, is greatly impacted by the level of maternal antibody to measles …

Background. The combined measles, mumps, and rubella (MMR) vaccine has been
successfully administered for> 20 years. Because of this, protection by maternal antibodies …

Context.—Measles causes serious morbidity in infants, with the highest risk among those
who are 6 to 12 months of age. In the United States, measles vaccine has been given at age …

Immunizing infants against measles at the youngest age possible has the potential to reduce
morbidity and mortality. The ability of infants at 6, 9, or 12 months to respond to measles and …

Abstract Background In Korea, measles occurs mainly in infants< 12 months of age, who are
unvaccinated. In addition, vaccine populations, including adolescents and young adults, can …

This paper reviews literature on passively transferred maternal antibodies against measles
in infants. The amount and decay of these antibodies can be a result of changing patterns in …

Measles infection in infants is associated with severe complications, and secondary
infections are attributed to generalized immunosuppression. Measles binding to its …

Evaluations of neutralizing antibody responses in 6-, 9-and 12-month-old infants given
measles or mumps vaccine indicated that 6-month-old infants had diminished humoral …

The decay of maternally derived antibodies to measles, mumps, and rubella viruses in Swiss
infants was studied in order to determine the optimal time for vaccination. A total of 500 …